ArticleEJHaem2025
Lynozyfic (Linvoseltamab): A First-in-Class Off-the-Shelf T-Cell Redirector for Refractory Multiple Myeloma.
Raza Ur RehmanPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleEJHaem2025
Raza Ur RehmanPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.